The David H. Koch Institute for Integrative Cancer Research at MITThe David H. Koch Institute for Integrative Cancer Research at MIT

Massachusetts Institute of Technology

National Cancer Institute Cancer Center

Science + Engineering... Conquering Cancer Together

Michael J. Cima, PhD

David H. Koch Professor in Engineering

 

 

KI Research Areas of Focus:
Nano-based Drugs, Detection + Monitoring,
Personalized Medicine

"We develop materials and engineered systems aimed at improving human health. Specifically, we are focused on diagnostics and treatments for cancer, metabolic diseases, trauma, and urological disorders. Our laboratory has expertise in advanced forming technologies for complex macro and micro devices, such as colloid science, MEMS and other micro components, as well as high-throughput development methods for formulations of materials and pharmaceutical formulations.  We are currently developing implantable MEMS devices for unprecedented control in the delivery of pharmaceuticals and implantable diagnostic systems."

Learn more about the Cima lab's work to create tiny nanosensors that are chemically sensitive to different molecules—and how they hope these sensors can be used to help determine proper dosage for chemotherapy—by watching the video: "Inside the Lab: Michael J. Cima, Ph.D.".

The Cima lab's work is profiled as part of the current interactive exhibits in the Koch Institute Public Galleries.  Watch a web version of the story here.

Dr. Michael J. Cima is the David H. Koch Professor of Engineering and a Professor of Materials Science and Engineering at the Massachusetts Institute of Technology and has an appointment at the David H. Koch Institute for Integrative Cancer Research.  He earned a B.S. in chemistry in 1982 (phi beta kappa) and a Ph.D. in chemical engineering in 1986, both from the University of California at Berkeley. Prof. Cima joined the MIT faculty in 1986 as an Assistant Professor.  He was promoted to full Professor in 1995.  He was elected a Fellow of the American Ceramics Society in 1997.  Prof. Cima was elected to the National Academy of Engineering in 2011.  He now holds the David H. Koch Chair of Engineering at MIT.  He was appointed faculty director of the Lemelson-MIT Program in 2009 which is a program to inspire youth to be inventive and has a nationwide reach. In 2018, Cima was named a co-director of MIT's Innovation Initiative and the associate dean of innovation for the School of Engineering.

Prof. Cima is author or co-author of over two hundred peer reviewed scientific publications, thirty seven US patents, and is a recognized expert in the field of materials processing.  Prof. Cima is actively involved in materials and engineered systems for improvement in human health such as treatments for cancer, metabolic diseases, trauma, and urological disorders.  Prof. Cima's research concerns advanced forming technology such as for complex macro and micro devices, colloid science, MEMS and other micro components for medical devices that are used for drug delivery and diagnostics, high-throughput development methods for formulations of materials and pharmaceutical formulations.  He is a coinventor of MIT’s three dimensional printing process.  His research has led to the development of chemically derived epitaxial oxide films for HTSC coated conductors.  He and collaborators are developing implantable MEMS devices for unprecedented control in the delivery of pharmaceuticals and implantable diagnostic systems.  Finally, through his consulting work he has been a major contributor to the development of high throughput systems for discovery of novel crystal forms and formulations of pharmaceuticals. 

Prof. Cima also has extensive entrepreneurial experience.  He is co-founder of MicroChips Inc., a developer of microelectronic based drug delivery and diagnostic systems.  Prof. Cima took two sabbaticals to act as senior consultant and management team member at Transform Pharmaceuticals Inc. a company that he helped start and that was ultimately acquired by Johnson and Johnson Corporation.  He is a co-founder and director at T2 Biosystems a medical diagnostics company.  Most recently, Prof. Cima co-founded SpringLeaf Therapeutics a specialty pharmaceutical company and Taris Biomedical a urology products company.

Further Information

Selected Publications

Tanenbaum LM, Mantzavinou A, Subramanyam KS, Del Carmen MG, Cima MJ. Gynecol Oncol. “Ovarian cancer spheroid shrinkage following continuous exposure to cisplatin is a function of spheroid diameter. 2017 Jul; 146(1):161-169. doi: 10.1016/j.ygyno.2017.04.014. Epub 2017 May 10. PMID: 28499648

Shawn M Davidson, Oliver Jonas, Mark A Keibler, Han Wei Hou, Alba Luengo, Jared R Mayers, Jeffrey Wyckoff, Amanda M Del Rosario, Matthew Whitman, Christopher R Chin, Kendall J Condon, Alex Lammers, Katherine A Kellersberger, Brian K Stall, Gregory Stephanopoulos, Dafna Bar-Sagi, Jongyoon Han, Joshua D Rabinowitz, Michael J Cima, Robert Langer, Matthew G Vander Heiden, “Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors” Nature Medicine, 2016/12/26/online,  advance online publication, http://dx.doi.org/10.1038/nm.4256

Hong AL, Tseng YY, Cowley GS, Jonas O, Cheah JH, Kynnap BD, Doshi MB, Oh C, Meyer SC, Church AJ, Gill S, Bielski CM, Keskula P, Imamovic A, Howell S, Kryukov GV, Clemons PA, Tsherniak A, Vazquez F, Crompton BD, Shamji AF, Rodriguez-Galindo C, Janeway KA, Roberts CW, Stegmaier K, van Hummelen P, Cima MJ, Langer RS, Garraway LA, Schreiber SL, Root DE, Hahn WC, Boehm JS. Integrated genetic and pharmacologic interrogation of rare cancers. Nat Commun. 2016 Jun 22; 7:11987.

Oudin MJ, Jonas O, Kosciuk T, Broye LC, Guido BC, Wyckoff J, Riquelme D, Lamar JM, Asokan SB, Whittaker C, Ma D, Langer R, Cima MJ, Wisinski KB, Hynes RO, Lauffenburger DA, Keely PJ, Bear JE, Gertler FB. Tumor Cell-Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression. Cancer Discov. 2016 May; 6(5):516-31. Epub 2016 Jan 25.

Jonas O, Oudin MJ, Kosciuk T, Whitman M, Gertler FB, Cima MJ, Flaherty KT, Langer R. Parallel in-vivo assessment of drug phenotypes at various time points during systemic BRAF inhibition reveals tumor adaptation and altered treatment vulnerabilities. Clin Cancer Res. 2016 Apr 18. pii: clincanres.2722.2015. [Epub ahead of print]

Ye H, Tanenbaum LM, Na YJ, Mantzavinou A, Fulci G, del Carmen MG, Birrer MJ, Cima MJ. Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models. J Control Release. 2015 Dec 28; 220(Pt A):358-67. Epub 2015 Nov 5.

H.N. Schwerdt, H. Shimazu, K. Amemori, S. Hong, J.C. Sy, K.C. Spencer, P.L. Tierney, Y. Yang, H. Yerramreddy, C. Dagdeviren, K. Ramadi, R.S. Langer, M.J. Cima, and A.M. Graybiel., Fast-scan cyclic voltammetric measurements of stimulation-induced dopamine release with chronically implanted carbon fibers in awake non-human primate, In Society for Neuroscience (SfN) Annual Meeting, 266.03/BB33, Chicago, IL, Oct. 2015.

Search PubMed for Cima lab publications

Articles and Media

Prof. Cima's work in researching implantable drug-delivery devices has been reported in the October 2002 and the June 2003 Technology Insider and the February 23, 2004 Boston Globe. As reported in Technology Insider, he presented this work at the New Materials track of the MIT Research and Development conference in November 2005.

His work on using nanoparticles in earlier detection of cancer was reported in the Oct. 31, 2005 Boston Globe. In Dec. 2006, the MIT News Office released a story on Prof. Cima's work in developing an implant that may assist doctors in measuring growth of tumors and progress of chemotherapy in cancer patients.

Contact Information

Michael J. Cima

room 76-653
phone (617) 253-6877
email mjcima@mit.edu

Cima Lab

website

Administrative Assistant:

Wendy Brown
phone (617) 253-2185
email webrown@mit.edu